Form 8-K
8-K — NEPHROS INC
Accession: 0001493152-26-050233
Filed: 2026-11-05
Period: 2026-08-06
CIK: 0001196298
SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — form8-k.htm (Primary)
EX-99.1 (ex99-1.htm)
GRAPHIC (ex99-1_001.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: form8-k.htm · Sequence: 1
false
0001196298
0001196298
2026-08-06
2026-08-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 6, 2026
NEPHROS,
INC.
(Exact
name of Registrant as Specified in its Charter)
Delaware
001-32288
13-3971809
(State
or other jurisdiction of
incorporation)
(Commission
File
Number)
(IRS
Employer
Identification No.)
380
Lackawanna Place, South
Orange, New
Jersey 07079
(Address
of principal executive offices, including ZIP code)
(201)
343-5202
(Registrant’s telephone number, including area code)
n/a
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which registered
Common
stock, $0.001 par value
NEPH
The
Nasdaq Stock Market LLC
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results
of Operations and Financial Condition.
On
November 5, 2026, Nephros, Inc. (the “Company”) issued a press release in which it disclosed its financial results for the
three and nine months ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1.
Pursuant
to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this
Item 2.02 have been furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section nor shall they be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth
by specific reference in such filing regardless of any general incorporation language.
Item 9.01. Financial
Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Nephros, Inc. Press Release, dated November 5, 2026.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by
the undersigned hereunto duly authorized.
Nephros, Inc.
Dated:
November 5, 2026
By:
/s/
Judy Krandel
Judy
Krandel
Chief
Financial Officer
EX-99.1
EX-99.1
Filename: ex99-1.htm · Sequence: 2
Exhibit 99.1
Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202
nephros.com
Nephros
Announces Strong Third Quarter 2026 Financial Results
Year
Over Year Net Revenue Growth of 18% and Core Programmatic Revenue Growth of 8% for the Three Months Ended September 30,
2026.
SOUTH
ORANGE, NJ, November 5, 2026 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions
to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2026.
Financial
Highlights
● Net
revenue increased 18% to $5.6 million, compared to $4.8 million in the third quarter of 2025
● Net
income was $0.5 million, compared to net income of $0.3 million in the third quarter of 2025
● Adjusted
EBITDA was $0.6 million, compared to $0.4 million in the third quarter of 2025
“The
third quarter of 2026 continued the strong momentum we have built across Nephros,” said Robert Banks, President and Chief Executive
Officer of Nephros. “Net revenue increased approximately 18% over the prior-year quarter to $5.6 million, following the record
$6.0 million we reported in the second quarter. Importantly, we continued to translate that growth into improved profitability, generating
net income of approximately $0.5 million and Adjusted EBITDA of approximately $0.6 million. Our performance through the first nine months
of the year reinforces our confidence in the underlying strength and durability of the business.”
Banks
continued, “One of the most encouraging indicators during the quarter was the continued expansion of our customer base. We added
approximately 31 new customer sites in the third quarter, bringing our active installed base to a record 1,766 sites. Healthcare remains
at the core of Nephros, representing approximately 64% of new sites added during the quarter, while approximately 17% came from commercial
and industrial customers and the remainder represented a diverse mix of government, military, hospitality, residential, retail and other
applications. This breadth is important. It demonstrates that the value of our filtration technology is increasingly being recognized
across applications beyond our traditional healthcare markets while we further expand our presence within healthcare. We continue to
leverage emerging industry standards, regulatory developments, and market intelligence to identify unmet needs, inform strategic priorities,
and support expansion into new applications and markets.”
Banks
added, “We are also seeing our strategy evolve beyond products alone. During the quarter, the Nephros Water Institute continued
a strong series of educational webinars, strengthening what we believe is becoming an important third pillar of our business alongside
products and service. Education allows us to engage customers and industry professionals around emerging water-quality challenges, share
the expertise we have developed over many years, and build relationships well before a filtration decision is made. We plan to deepen
our investment in education as a driver of commercial growth and market development. We believe educational programming increases awareness
of water safety challenges and available solutions, generates qualified leads, and sustains engagement with prospective customers throughout
the sales cycle, supporting conversion and product adoption. We further believe the combination of differentiated products, service capabilities
and education increasingly distinguishes Nephros in the markets we serve.”
Banks
concluded, “As we enter the final quarter of 2026, our focus remains on execution. We have grown trailing twelve-month revenue
to more than $21 million, expanded our active customer base, remained profitable, and continued investing in the products, services and
capabilities that we believe can support the next stage of growth. Competition continues to evolve and the broader economic environment
remains uncertain, but we believe Nephros is entering the final months of the year from a position of strength. Our objective is simple:
finish 2026 strong and continue building a larger, more predictable and more valuable company for our shareholders.”
1
Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202
nephros.com
Financial
Performance for the Quarter Ended September 30, 2026
Net
revenue for the three months ended September 30, 2026, and 2025 was $5.6 million and $4.8 million, respectively, an increase of 18%.
This increase was driven primarily by increased product revenue from programmatic growth, which grew by 8% over the same period in 2025
as well as significant growth in emergency response revenue. In addition, the company reported growth in service revenue.
Cost
of goods sold for the third quarter of 2026 was $2.3 million, compared with $1.8 million in the third quarter of 2025, an increase of
26%.
Gross
margin for the third quarter of 2026 was 58%, compared with 61% in the third quarter of 2025. The decrease of approximately three percentage
points was primarily attributable to higher inventory shipping and handling costs, including tariff expense, and growth in service revenue,
which yields lower gross margins than product sales.
Selling,
general and administrative expenses for the third quarter of 2026 were approximately $2.4 million, compared with $2.2 million in 2025,
an increase of 9% due to increases in headcount and an increase in professional fees.
Research
and development expenses for the third quarter of 2026 were approximately $331,000, compared with $338,000 in the third quarter of 2025,
a decrease of 2%.
Depreciation
and amortization expenses for the third quarter of 2026 were approximately $29,000, compared with approximately $34,000 in the third
quarter of 2025.
Net
income for the third quarter of 2026 increased to $0.5 million, compared with $0.3 million during the same period in 2025.
Adjusted
EBITDA for the third quarter 2026 increased to approximately $0.6 million, compared with approximately $0.4 million in the third quarter
of 2025.
Financial
Performance for the Nine Months Ended September 30, 2026
Net
revenue for the nine months ended September 30, 2026, and 2025 was $16.9 million, and $14.1 million respectively, an increase of 20%.
Core programmatic revenue grew by 19% over the same period in 2025. The increase in programmatic sales reflects strong reorders, and
a number of new active sites. In addition, service revenue experienced strong growth.
Cost
of goods sold for the nine months ended September 30, 2026 and 2025 was $6.5 million, and $5.2 million respectively, an increase of 26%.
Gross margin for the nine months ended September 30, 2026 was 61%, compared with 63% during the same period in 2025. The decrease was
primarily attributable to increased product costs due to the weakening of the U.S. dollar compared to the Euro, and rapid revenue growth
from commercial products offerings and services revenue, both of which yield lower gross margins than the infection control business.
However, gross margins significantly benefited from the recognition during the 2026 period of the IEEPA tariff refund of approximately
$0.6 million, which was recorded as a reduction of cost of goods sold during the nine months ended September 30, 2026. This refund reflects
tariffs paid by Nephros from April 2025 to February 2026. Approximately $0.3 million of this tariff refund corresponds to purchased inventory
that was converted to revenue in 2026. The remaining approximately $0.3 million of the refunded tariffs correspond to purchased inventory
that was converted to revenue in 2025, of which approximately $0.2 million corresponds to purchased inventory that was converted to revenue
in the nine months ended September 30, 2025.
2
Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202
nephros.com
Selling,
general and administrative expenses for the nine months ended September 30, 2026 and 2025 were approximately $7.4 million, and $6.7 million
respectively, an increase of 10% primarily due to an increase in headcount and an increase in professional fees.
Research
and development expenses for the nine months ended September 30, 2026 and 2025 were $1.0 million and $0.9 million respectively.
Depreciation
and amortization expenses for the nine months ended September 30, 2026 and 2025 were approximately $87,000, and $108,000 respectively.
As
a result of the improved sales, net income for the nine months ended September 30, 2026 increased to $1.8 million compared to $1.1 million
during the same period in 2025.
Adjusted
EBITDA for the nine months ended September 30, 2026 increased to approximately $2.0 million, compared with approximately $1.4 million
in the same period of 2025.
As
of September 30, 2026, Nephros had cash and cash equivalents of approximately $4.5 million, compared to $5.4 million as of December 31,
2025, and remains debt free.
Adjusted
EBITDA Definition and Reconciliation to GAAP Financial Measures
Adjusted
EBITDA is calculated by taking net income calculated in accordance with generally accepted accounting principles (“GAAP”)
and excluding all interest-related expenses and income, tax-related expenses and income, and non-cash items, including depreciation,
amortization, non-cash inventory write-offs, and non-cash compensation. The following tables present a reconciliation of Adjusted EBITDA
to net income, the most directly comparable GAAP financial measure, for the third quarter of the 2026 fiscal year:
(unaudited)
Three Months Ended September 30,
2026
2025
(in $ thousands)
Net income
512
337
Adjustments:
Depreciation of property and equipment
11
12
Amortization of other assets
20
22
Interest expense
-
-
Interest income
(53 )
(41 )
Income taxes
-
3
Non-cash stock-based compensation
60
70
Non-cash inventory impairments
8
15
Adjusted EBITDA Income
558
418
(unaudited)
Nine Months Ended September 30,
2026
2025
(in $ thousands)
Net income
1,849
1,132
Adjustments:
Depreciation of property and equipment
34
42
Amortization of other assets
52
65
Interest expense
1
1
Interest income
(115 )
(85 )
Income taxes
13
12
Non-cash stock-based compensation
181
217
Non-cash inventory impairments
30
56
Adjusted EBITDA Income
2,045
1,440
3
Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202
nephros.com
Nephros
believes that Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends
relating to Nephros’ financial condition and results of operations. Management does not consider Adjusted EBITDA in isolation or
as an alternative to financial measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA is that it excludes
significant expenses and income that are required by GAAP to be recognized in Nephros’ financial statements. In addition, Adjusted
EBITDA is subject to inherent limitations as it reflects the exercise of judgments by management about which expenses and income are
excluded or included in determining Adjusted EBITDA. To compensate for these limitations, management presents Adjusted EBITDA in connection
with net income, the most directly comparable GAAP financial measure. Nephros urges investors to review the reconciliation of Adjusted
EBITDA to net income and not to rely on any single financial measure to evaluate the business.
Conference
Call Today at 4:30pm Eastern Time
Nephros
will host a conference call today at 4:30pm ET, during which management will discuss Nephros’ financial results and provide a general
business overview.
Participants
may dial into the call as follows:
Domestic access: 1 (646) 307-1963
International access: (800) 715-9871
Upon
joining, please ask to be joined into the Nephros conference call.
An
audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.
Alternatively,
a replay of the call may be accessed until November 12, 2026 at 1-855-669-9658 or
1-412-317-0088 for international callers and entering replay access code: 8234499
About
Nephros
Nephros
is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration
products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the
needs of customers within healthcare and commercial markets, offering both proactive and emergency solutions for water management.
For
more information about Nephros, please visit nephros.com.
Forward-Looking
Statements
This
release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding
Nephros’ expected future business, revenue and gross margin growth and the timing of such growth, the drivers of our revenue growth,
the effect of new regulations on future revenue growth, Nephros’ ability to continue to grow its product and service offerings
beyond traditional healthcare markets, the expected competitive advantages and anticipated impact of new product and service offerings
and market expansions, and other statements that are not historical facts, including statements that may be accompanied by the words
“intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”
“potential” or similar words. Actual results could differ materially from those described in these forward-looking statements
due to certain factors, including Nephros’ ability to further develop its sales organization and realize increased revenues, the
extent to which financial results based on emergency response sales can be outside Nephros’ control, the extent to which U.S. tariffs
may increase our expenses, inflationary factors and other economic and competitive conditions, the availability of capital when needed,
dependence on third-party manufacturers and researchers, and regulatory reforms. These and other risks and uncertainties are detailed
in Nephros’ reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year
ended December 31, 2025, which it may update in Part II, Item 1A – Risk Factors in its Quarterly Reports on Form 10-Q that it has
filed or will file hereafter. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks
only as of the date of this release, and Nephros does not undertake any responsibility to update any forward-looking statements that
it makes, except as may be required by law.
Investor
Relations Contacts:
Kirin
Smith, President
PCG Advisory, Inc.
(646) 823-8656
ksmith@pcgadvisory.com
Robert
Banks, CEO
Nephros, Inc.
(201) 343-5202 x110
robert.banks@nephros.com
4
Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202
nephros.com
NEPHROS,
INC.
BALANCE
SHEETS
(In
thousands, except share and per share amounts)
(Unaudited)
September 30, 2026
December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents
$ 4,546
$ 5,400
Accounts receivable, net
3,583
2,414
Inventory
4,953
3,232
Prepaid expenses and other current assets
174
177
Total current assets
13,256
11,223
Property and equipment, net
72
106
Lease right-use-of assets
735
1,021
Intangible assets, net
294
318
Goodwill
759
759
License and supply agreement, net
139
164
Other assets
50
50
TOTAL ASSETS
$ 15,305
$ 13,641
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
850
914
Accrued expenses
1,133
1,462
Current portion of lease liabilities
426
391
Total current liabilities
2,409
2,767
Lease liabilities, net of current portion
348
672
TOTAL LIABILITIES
2,757
3,439
STOCKHOLDERS’ EQUITY:
Preferred stock, $.001 par value; 5,000,000 shares authorized at September 30, 2026 and December 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025.
-
-
Common stock, $.001 par value; 40,000,000 shares authorized at September 30, 2026 and December 31, 2025; 10,870,004 and 10,644,268 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively
11
11
Additional paid-in capital
153,826
153,329
Accumulated deficit
(141,289 )
(143,138 )
TOTAL STOCKHOLDERS’ EQUITY
12,548
10,202
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
$ 15,305
$ 13,641
5
Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202
nephros.com
NEPHROS, INC.
STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(Unaudited)
Three Months Ended September 30,
Nine Months Ended September 30,
2026
2025
2026
2025
Net revenue:
Product revenues
$ 5,431
$ 4,596
$ 16,172
$ 13,613
Service, royalty and other revenues
191
168
679
447
Total net revenues
5,622
4,764
16,851
14,060
Cost of goods sold
2,336
1,849
6,546
5,196
Gross margin
3,286
2,915
10,305
8,864
Operating expenses:
Selling, general and administrative
2,425
2,229
7,364
6,684
Research and development
331
338
1,043
944
Depreciation and amortization
29
34
87
108
Total operating expenses
2,785
2,601
8,494
7,736
Operating income
501
314
1,811
1,128
Other (expense) income:
Interest expense
-
-
(1 )
(1 )
Interest income
53
41
115
85
Other income (expense), net
(42 )
(15 )
(63 )
(68 )
Total other expense:
11
26
51
16
Income (loss) before income taxes
512
340
1,862
1,144
Income tax expense
-
(3 )
(13 )
(12 )
Net income
$ 512
$ 337
$ 1,849
$ 1,132
Net income per common share, basic
$ 0.05
$ 0.03
$ 0.17
$ 0.11
Net income per common share, diluted
$ 0.05
$ 0.03
$ 0.17
$ 0.10
Weighted average common shares outstanding, basic
10,863,253
10,612,012
10,790,982
10,604,300
Weighted average common shares outstanding, diluted
11,203,973
11,040,925
11,096,826
10,846,477
6
GRAPHIC
GRAPHIC
Filename: ex99-1_001.jpg · Sequence: 3
Binary file (9375 bytes)
Download ex99-1_001.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.3
Cover
Aug. 06, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Aug. 06, 2026
Entity File Number
001-32288
Entity Registrant Name
NEPHROS,
INC.
Entity Central Index Key
0001196298
Entity Tax Identification Number
13-3971809
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
380
Lackawanna Place
Entity Address, City or Town
South
Orange
Entity Address, State or Province
NJ
Entity Address, Postal Zip Code
07079
City Area Code
(201)
Local Phone Number
343-5202
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common
stock, $0.001 par value
Trading Symbol
NEPH
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration